This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

22 Biopharma Stocks With Breakout Potential in 2012

BOSTON ( TheStreet) -- Drug approval decisions garner big headlines, but savvy and successful biotech investors know that making smart trading decisions ahead of important clinical trial results is the ticket to banking serious coin.

The market value of Vertex Pharmaceuticals (VRTX) has jumped by $5 billion in the past three weeks based solely on positive, interim results from a phase II cystic fibrosis trial. That stands in stark contrast to Vertex's falling stock price following the approval of its hepatitis C drug Incivek.

Only in biotech can a single event like the announcement of new clinical data lead to such incredible and immediate profits for investors. Like the lottery slogan says, "You have to be in it, to win it," which for biotech investors and traders means knowing in advance the companies conducting important clinical trials and when to expect the announcement of results.

To kick-start the research process, I've compiled a list of 21 drugs and a single diagnostic test currently involved in phase II and phase III trials. Importantly, results from these clinical trials are all expected before the end of the year. [Some as early as by the end of the current quarter.]

I can't guarantee that any or all of these biotech and drug stocks will mimic the spectacular stock return delivered by Vertex in May, but there are surely some rockets on this list. Happy Hunting!

[For ease of use, I've organized the list of 2012 clinical trials in alphabetical order by the company developing the drug. All timelines for data announcements are best estimates based on company guidance.]

Without further adieu: The must-know list of 2012 clinical trials:

Acadia Pharmaceuticals (ACAD - Get Report)
Drug/indication: Pimavanserin in Parkinson's disease psychosis (phase III study)
Top-line results expected in the third quarter of 2012
The "020" trial compares pimavanserin against placebo in patients suffering from psychosis due to Parkinson's disease. The primary endpoint is the reduction in antipsychotic behavior measured using the Scale for the Assessment of Positive Symptoms (SAPS).
Two previous phase III studies of pimavanserin in patients with Parkinson's psychosis failed to demonstrate a statistically significant benefit. The ongoing "020" study was designed to diminish the effect of a placebo response and produce data that are less subject to variability.

Amicus Therapeutics (FOLD)
Drug/indication: migalastat (Amigal) in Fabry disease
Top-line results expected in the third quarter 2012
"Study 011" compares migalastat to a placebo in patients with Fabry disease. A second phase III study "013" compares migalastat against current standard-of-care therapies for Fabry disease, Fabrazyme or Replagal.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
ACAD $27.53 -8.23%
ARQL $1.57 2.61%
BIIB $263.12 -3.87%
GERN $2.73 -3.87%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs